Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...Cole Pinnow, president of Pfizer Canada, said it was a “historic moment” and a “major step towards returning to normalcy in Canada”....
...Hungary is the only EU member to have approved both the Chinese-made Sinopharm and Russian-made Sputnik V vaccines....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...There has also been a 25 per cent rise in health spending, as households load up on pharmaceuticals....
...Record label Warner Music and shoe maker Cole Haan have both delayed IPOs; Micro Focus, one of Britain’s largest listed technology businesses, shelved a $1.4bn loan on Monday; and Bausch Health has put its...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...Mr Coles had raised cash at a time when investors were fleeing biotech companies amid fears of a bubble....
...Its first round of anti-inversion measures in 2014 eventually killed another pharmaceuticals deal, AbbVie’s planned $54bn takeover of UK-listed Shire, although the market reaction was not as instantaneous...
...But if Japan Inc has overpaid in the past 12 months the motivation for doing so seems clear: business survival....
...The problem with robotic surgery has been the expense, says Emmet Cole, a Texas-based technology writer who specialises in robot technology....
...The appointment of Greg Callus, an experienced barrister — created a new locus of authority in the newsroom, albeit strictly in the appellate role....
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
...Tencent Holdings, the gaming and social networking group, and Baidu Inc, the search provider, have also launched similar products....
...Alongside her is Ken Cole, a former General Motors’ lobbyist who left for the drug company after working on the US auto sector bailout....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
International Edition